Mayinglong Pharmaceutical Group Co., Ltd. (SHA:600993)
27.47
+0.28 (1.03%)
Feb 3, 2026, 3:00 PM CST
SHA:600993 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,725 | 3,680 | 3,098 | 3,497 | 3,363 | 2,775 |
Other Revenue | 48.5 | 48.5 | 38.3 | 35.12 | 22.53 | 16.54 |
| 3,773 | 3,728 | 3,137 | 3,532 | 3,385 | 2,792 | |
Revenue Growth (YoY) | 8.36% | 18.85% | -11.20% | 4.35% | 21.26% | 3.19% |
Cost of Revenue | 1,984 | 1,997 | 1,829 | 2,038 | 2,019 | 1,688 |
Gross Profit | 1,790 | 1,731 | 1,307 | 1,494 | 1,366 | 1,104 |
Selling, General & Admin | 1,078 | 1,051 | 825.21 | 886.06 | 818.05 | 668.73 |
Research & Development | 73.78 | 66.69 | 69.01 | 77.89 | 66.73 | 55.66 |
Other Operating Expenses | 29.01 | 26.29 | 24.39 | 26.16 | 25.06 | 20.91 |
Operating Expenses | 1,188 | 1,153 | 922.54 | 1,000 | 912.9 | 754.83 |
Operating Income | 602.3 | 578.43 | 384.73 | 494.16 | 453.38 | 349.08 |
Interest Expense | -8.54 | -7.38 | -16.85 | -11.69 | -10.21 | -6.98 |
Interest & Investment Income | 68.26 | 78.88 | 151.5 | 98.92 | 78.85 | 30.4 |
Currency Exchange Gain (Loss) | -0.06 | -0.06 | 0.05 | 0.04 | -0.21 | -0.06 |
Other Non Operating Income (Expenses) | 4.77 | 0.99 | -3.78 | -6.22 | -4.92 | -5.08 |
EBT Excluding Unusual Items | 666.74 | 650.87 | 515.65 | 575.22 | 516.89 | 367.36 |
Gain (Loss) on Sale of Investments | 13.66 | -6.57 | -0.35 | -38.06 | 17.63 | 100.55 |
Gain (Loss) on Sale of Assets | -0.7 | -0.14 | 1.12 | -0.01 | -0.5 | 7.58 |
Asset Writedown | 0.99 | -5.25 | - | -0.34 | -0.44 | -0.42 |
Other Unusual Items | 16.08 | 18.64 | 8.28 | 22.33 | 14.58 | 22.62 |
Pretax Income | 696.76 | 657.55 | 524.7 | 559.14 | 548.16 | 497.69 |
Income Tax Expense | 101.37 | 109.26 | 72.86 | 79.78 | 74.11 | 67.05 |
Earnings From Continuing Operations | 595.4 | 548.3 | 451.84 | 479.35 | 474.05 | 430.64 |
Minority Interest in Earnings | -23.8 | -20.2 | -8.59 | -0.78 | -9.46 | -11.58 |
Net Income | 571.6 | 528.09 | 443.25 | 478.57 | 464.59 | 419.06 |
Net Income to Common | 571.6 | 528.09 | 443.25 | 478.57 | 464.59 | 419.06 |
Net Income Growth | 18.50% | 19.14% | -7.38% | 3.01% | 10.87% | 16.42% |
Shares Outstanding (Basic) | 430 | 429 | 430 | 431 | 430 | 432 |
Shares Outstanding (Diluted) | 430 | 429 | 430 | 431 | 430 | 432 |
Shares Change (YoY) | -0.23% | -0.23% | -0.19% | 0.22% | -0.43% | 0.81% |
EPS (Basic) | 1.33 | 1.23 | 1.03 | 1.11 | 1.08 | 0.97 |
EPS (Diluted) | 1.33 | 1.23 | 1.03 | 1.11 | 1.08 | 0.97 |
EPS Growth | 18.77% | 19.42% | -7.21% | 2.78% | 11.34% | 15.48% |
Free Cash Flow | 545.93 | 293.76 | 355.7 | 266.84 | 532.07 | 237.58 |
Free Cash Flow Per Share | 1.27 | 0.68 | 0.83 | 0.62 | 1.24 | 0.55 |
Dividend Per Share | 0.620 | 0.620 | 0.400 | 0.350 | 0.350 | 0.300 |
Dividend Growth | 55.00% | 55.00% | 14.29% | - | 16.67% | 15.38% |
Gross Margin | 47.44% | 46.43% | 41.68% | 42.30% | 40.36% | 39.54% |
Operating Margin | 15.96% | 15.52% | 12.26% | 13.99% | 13.39% | 12.50% |
Profit Margin | 15.15% | 14.17% | 14.13% | 13.55% | 13.73% | 15.01% |
Free Cash Flow Margin | 14.47% | 7.88% | 11.34% | 7.55% | 15.72% | 8.51% |
EBITDA | 641.53 | 622.05 | 434.2 | 541.14 | 495.12 | 384.34 |
EBITDA Margin | 17.00% | 16.69% | 13.84% | 15.32% | 14.63% | 13.77% |
D&A For EBITDA | 39.24 | 43.62 | 49.48 | 46.98 | 41.74 | 35.25 |
EBIT | 602.3 | 578.43 | 384.73 | 494.16 | 453.38 | 349.08 |
EBIT Margin | 15.96% | 15.52% | 12.26% | 13.99% | 13.39% | 12.50% |
Effective Tax Rate | 14.55% | 16.61% | 13.89% | 14.27% | 13.52% | 13.47% |
Revenue as Reported | 3,773 | 3,728 | 3,137 | 3,532 | 3,385 | 2,792 |
Advertising Expenses | - | 161.64 | 72.56 | 81.25 | 59.99 | 49.06 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.